Tonix Pharmaceuticals shares are trading higher after the company secured a second commercial payer agreement for TONMYA, its newly launched fibromyalgia treatment. The update improves potential reimbursement access and supports early commercialization efforts, but it does not include sales or financial data. The news is positive for sentiment and may modestly support the stock.
Tonix Pharmaceuticals shares are trading higher after the company secured a second commercial payer agreement for TONMYA, its newly launched fibromyalgia treatment. The update improves potential reimbursement access and supports early commercialization efforts, but it does not include sales or financial data. The news is positive for sentiment and may modestly support the stock.
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialOverall Sentiment
mildly positive
Sentiment Score
0.35
Ticker Sentiment
